Increased risk for breast cancer death among black women is greatest during early postdiagnosis years

Share this article:

Non-Hispanic black women with breast cancer, specifically estrogen-positive tumors, are at a significantly increased risk for breast cancer death compared with non-Hispanic white women. The difference is greatest in the first 3 years after diagnosis.

Prior research has shown that non-Hispanic black women have a lower breast cancer survival rate relative to other racial/ethnic groups. This research included 19,480 women who presented to National Comprehensive Cancer Network (NCCN) centers with stage I to stage III breast cancer between January 2000 and December 2007. Breast cancer-specific mortality was compared among 634 Asian women, 1,291 Hispanic women, 1,500 non-Hispanic black women, and 16,055 non-Hispanic white women. The median follow-up was 6.9 years.

The non-Hispanic black women had a 48% higher risk for breast cancer death in the first 3 years after diagnosis compared with non-Hispanic white women. After 3 years, non-Hispanic black women had a 34% increased risk for breast cancer-specific mortality.

Those non-Hispanic black women whose tumors were estrogen receptor-positive were more than twice as likely to die from breast cancer within 3 years of diagnosis compared with non-Hispanic white women. This risk was also increased in non-Hispanic black women with luminal A and luminal B breast cancer subtypes.

“The higher risk for early death among black women was more striking among women with estrogen receptor-positive tumors. This finding is important because these are the types of tumors that we traditionally think of as more treatable,” said Erica Warner, MPH, ScD, postdoctoral fellow at the Harvard School of Public Health. Breast cancer mortality had no difference between non-Hispanic black and white women with estrogen receptor-negative, basal, or HER2-overexpressing tumor subtypes.

“The results of this study emphasize that clinical management and follow-up for patients with breast cancer, particularly black women, is important in the first few years after diagnosis,” Warner said. “Although the difference between blacks and whites was highest for this time period, the risk for death was highest in the first few years after diagnosis for all groups.”

This data was presented at the Fifth American Association for Cancer Research Conference on The Science of Cancer Health Disparities in San Diego.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Molecular subtyping can improve breast cancer treatment

The BluePrint genomic test provides more accurate information about the molecular subtype of a specific breast cancer, compared with the use of conventional IHC-FISH pathology tests, according to a new study.

'Overdiagnosis' in breast cancer screening is still not understood

One-third of women who are given information about the potential for over-diagnosis through the National Health Services (NHS) breast screening program may not completely understand the risks involved.

Lifestyle and genetics strongly impact biomarkers for inflammation and cancer

Genetics and lifestyle influence protein levels in the bloodstream, and this discovery greatly influences the possibilities for using more biomarkers to identify disease.